87304-15-2

Usage

Uses

Used in Biochemistry and Pharmacology Research:
(2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid is utilized as a reference standard in biochemical and pharmacological research. Its well-defined structure and functional groups make it a valuable tool for understanding the interactions between peptides and biological systems.
Used in Synthesis of Peptides and Pharmaceuticals:
(2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid serves as a building block for the synthesis of peptides and pharmaceuticals. Its unique structure allows it to be incorporated into larger molecules with specific biological activities, potentially leading to the development of new drugs and therapeutic agents.
Used in Therapeutic Applications:
Due to its interactions with biological systems and enzymes, (2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid may have potential therapeutic applications. Its complex structure and functional groups could contribute to its efficacy in treating various diseases or conditions, although further research is needed to explore these possibilities.

Upstream product

• 62023-65-8 (2S,3R)-3-[(tert-butoxycarbonyl) amino]-2-hydroxy-4-phenyl-butanoic acid 
• 81926-51-4 N-(tert-butyloxycarbonyl)-(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester 
• 77119-86-9 methyl ((2S,3R)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-4-phenylbutanoyl)-L-leucinate 
• 59554-14-2 (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 58970-76-6 bestatin 
• 246506-78-5 2-(3-tert-butoxycarbonylamino-2-oxo-4-phenylbutyrylamino)-4-methylpentanoic acid benzyl ester 
• 18942-49-9 Boc-D-Phe-OH 
• 246506-75-2 [1-benzyl-3-cyano-2-oxo-3-(triphenyl-λ⁵-phosphanylidene)-propyl]-carbamic acid tert-butyl ester 
• 172025-60-4 (2S,3R)-3-Azido-2-hydroxy-4-phenyl-butyric acid methyl ester 
• 612096-23-8 (2R,3S)-3-Bromo-2-hydroxy-4-phenyl-butyric acid methyl ester 
• 182699-39-4 (2S,3R)-methyl-2,3-epoxy-4-phenylbutanoic acid 
• 869115-78-6 (2S,3R)-2-Acetoxy-3-tert-butoxycarbonylamino-4-phenyl-butyric acid 
• 869115-77-5 (2S,3R)-2-Acetoxy-3-amino-4-phenyl-butyric acid 

Downstream Products

• 246506-80-9 1-{1-[2-(3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutyrylamino)-4-methyl-pentanoyl]pyrrolidine-2-carbonyl}-pyrrolidine-2-carboxylic acid benzyl ester 
• 58970-76-6 bestatin 
• 1041865-45-5 (S)-2-[1-(dimethylamino)naphthalene-5-sulfonamido]ethyl 2-[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanamido]-4-methylpentanoate 
• 1312302-10-5 tert-butyl (2R,3S)-3-hydroxy-4-[(S)-4-methyl-1-(methylamino)-1-oxopentan-2-ylamino]-4-oxo-1-phenylbutan-2-ylcarbamate 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy

In our previous study, we discovered a ubenimex-fluorouracil (5FU) conjugates BC-02, which displays significant in vivo anti-tumor activity, however, the instability of BC-02 in plasma limits its further development as a drug candidate. Herein, we designe

Discovery of a novel chimeric ubenimex–gemcitabine with potent oral antitumor activity

Herein, a novel mutual prodrug BC-A1 was discovered by integrating ubenimex and gemcitabine into one molecule. Biological characterization revealed that compound BC-A1 could maintain both the anti-CD13 activity of ubenimex and the cytotoxic activity of ge

TUBULIN BINDING AGENTS

The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature.

Synthesis and activity evaluation of a new bestatin derivative LYP2 as an aminopeptidase N inhibitor

As a ubiquitous enzyme overexpressed on the epithelium of the tumor, aminopeptidase N (APN) plays important roles in the angiogenesis and metastasis of the tumor. Bestatin as an effective inhibitor against APN is used in the ancillary treatment of various

Development of target protein-selective degradation inducer for protein knockdown

Our previous technique for inducing selective degradation of target proteins with ester-type SNIPER (Specific and Nongenetic Inhibitor-of-apoptosis- proteins (IAPs)-dependent Protein ERaser) degrades both the target proteins and IAPs. Here, we designed a

Demonstration of direct binding of cIAP1 degradation-promoting bestatin analogs to BIR3 domain: Synthesis and application of fluorescent bestatin ester analogs

Overexpression of cIAP1 correlates with resistance to radiotherapy and chemotherapy in various cancers. Recently, we reported that a class of bestatin ester analogs represented by MeBS (2) destabilized and promoted the degradation of cIAP1 through auto-ub

A total synthesis of (-)-bestatin using Shibasaki's asymmetric Henry reaction

A total synthesis of the potent aminopeptidase inhibitor (-)-bestatin has been achieved using Shibasaki's asymmetric Henry reaction catalyzed by an optically active rare earth lanthanum-(R)-binaphthol complex in 26% overall yield.

New stereoselective synthesis of the peptidic aminopeptidase inhibitors bestatin, phebestin and probestin

Peptidic aminopeptidase inhibitors, bestatin, phebestin and probestin have been prepared by stereo- and regiocontrolled reactions from a common α,β-epoxy ester precursor.

Application of acyl cyanophosphorane methodology to the synthesis of protease inhibitors: Poststatin, eurystatin, phebestin, probestin and bestatin

Full details are given for the syntheses of the protease inhibitors, poststatin and eurystatin by the acyl cyanophosphorane coupling procedure used for the formation of α-keto amides. We have also extended this methodology to the syntheses of the related α-hydroxy amide natural products, phebestin, probestin and bestatin. The key step in the latter synthetic sequences involved diastereomeric selectivity in the reduction of the α-keto precursor to the corresponding α-hydroxy amide by the use of zinc borohydride.

Synthesis of the peptidic α-hydroxy amides phebestin, probestin, and bestatin from α-keto amide precursors

Aminopeptidase inhibitors, phebestin, probestin and bestatin have been prepared by stereospecific reduction of α-keto amide precursors using zinc borohydride.